EyePoint Pharmaceuticals

Press Releases

pSivida CEO to Discuss Sustained Delivery of Antibodies in Ophthalmology and Systemic Disease at International Symposium on Integrated Functionalities
Jul 29, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, has announced that pSivida President and Chief Executive Officer, Paul Ashton , Ph.D., will speak
pSivida Announces France's Transparency Commission Issues Positive Opinion for Reimbursement of ILUVIEN
Jul 24, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the Transparency Commission (Commission de la Transparence or CT) of the French
pSivida Announces Pricing of $10.8 Million Offering of Common Stock
Jul 19, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (Nasdaq: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced that it has priced an underwritten public offering of 3,494,550 shares of its
pSivida Announces Proposed Public Offering of Common Stock
Jul 18, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (Nasdaq: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced that it intends to offer and sell shares of its common stock in a proposed
pSivida Corp. Announces Interim Data From Investigator-Sponsored Uveitis Study
Jul 11, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced interim data from an investigator-sponsored Phase I/II study of pSivida's
pSivida Corp. Announces Initiation of Phase III Clinical Trial in Posterior Uveitis
Jul 01, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that it has initiated the first of two planned pivotal Phase III trials of its
pSivida Corp. Announces UK's NICE Says Yes to ILUVIEN® in Some Patients with Diabetic Macular Edema in New Draft Guidance
Jun 14, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV - News ), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Excellence (NICE) issued draft
pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company
May 29, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that it has signed a funded technology evaluation agreement with a leading global
pSivida Corp. Reports Third Quarter Fiscal Year 2013 Results
May 13, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its third quarter ended March 31, 2013 .
pSivida Corp. Announces Commercial Launch of ILUVIEN® in Germany with First Patient Treated
May 07, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV - News ), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that ILUVIEN ® , the first sustained release pharmaceutical product for the treatment of chronic
pSivida Corp. Announces Third Quarter 2013 Financial Results Release Date and Conference Call Information
May 06, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the third quarter of fiscal year 2013 will be released after the
pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013
May 01, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV - News ), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the U.S. Food and Drug Administration (FDA) acknowledged receipt of the resubmission of the New
pSivida Reports ILUVIEN® Available in UK
Apr 29, 2013
Simple Patient Access Scheme Submitted to NICE for Rapid Review WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced ILUVIEN® , the first
pSivida Announces Launch of New Online Corporate Communication Channels
Apr 10, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced the launch of a suite of online corporate communication channels to communicate
pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company
Apr 04, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that it has signed a funded technology evaluation agreement with a leading global
pSivida Reports on Resubmission to FDA of NDA for ILUVIEN® for Chronic Diabetic Macular Edema
Apr 01, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc.
pSivida Reports Updates on ILUVIEN® for Planned Resubmission to FDA and European Launch
Mar 22, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc.
pSivida VP of Research to Discuss Company's Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug Development Conference
Mar 20, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that the Company's Vice President of Research, Dr.
pSivida Corp. Reports Second Quarter Fiscal Year 2013 Results
Feb 06, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its second quarter ended December 31, 2012 .
pSivida CEO to Present at 15th Annual BioCEO & Investor Conference February 12
Feb 04, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), an emerging specialty pharmaceutical company and leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its President and CEO, Dr.
Displaying 161 - 180 of 326
EyePoint Pharmaceuticals